Booking Holdings Inc. (BKNG) vs Vertex Pharmaceuticals Incorporated (VRTX)
A side-by-side comparison of Booking Holdings Inc. and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 10, 2026. Differences are shown without an overall score or investment verdict.
Different business models: BKNG is classified in Consumer Cyclical; VRTX is classified in Healthcare. Margin, capital intensity, and valuation differences should be interpreted in that sector context.
BKNG
Booking Holdings Inc.
$173.92Consumer CyclicalDelayed quote: Sep 11, 2026, 4:00 PM EDT
VRTX
Vertex Pharmaceuticals Incorporated
$515.44HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT
Total return — BKNG vs VRTX
growth of $100 · dividends reinvested · last 10yBKNG +215.3% (+12.2%/yr)VRTX +462.1% (+18.8%/yr)VRTX compounded faster over this window
BKNG VRTX
BKNG vs VRTX: by the numbers
- •BKNG is the larger company ($134.77B vs $130.82B market cap).
- •BKNG trades at the lower trailing earnings multiple (19.29 vs 30.00 P/E), one valuation lens rather than an overall verdict.
- •VRTX converts more revenue to profit (34.89% vs 25.53% net margin).
- •BKNG grew revenue faster over the past five years (31.52% vs 13.57% CAGR).
- •BKNG pays a dividend (0.92% yield), while VRTX has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | BKNG | VRTX |
|---|---|---|
| P/E ratio | 19.29 | 30.00 |
| Forward P/E | 16.64 | 27.49 |
| P/S ratio | 4.77 | 10.36 |
| P/B ratio | N/A | 6.46 |
| EV / EBITDA | 13.30 | 24.88 |
| FCF yield | 7.08% | 2.90% |
Profitability
| Metric | BKNG | VRTX |
|---|---|---|
| Gross margin | 100.00% | 86.04% |
| Operating margin | 34.49% | 38.59% |
| Net margin | 25.53% | 34.89% |
| ROE | N/A | 21.76% |
| ROIC | 71.23% | 17.33% |
Dividends
| Metric | BKNG | VRTX |
|---|---|---|
| Dividend yield | 0.92% | N/A |
| Payout ratio | 17.83% | N/A |
Growth (annualized)
| Metric | BKNG | VRTX |
|---|---|---|
| Revenue CAGR (5Y) | 31.52% | 13.57% |
| EPS CAGR (5Y) | 158.62% | 8.17% |
| FCF CAGR (5Y) | 56.15% | 16.39% |
| Total return CAGR (5Y) | 14.07% | 22.61% |
Frequently asked
- Which has the lower trailing P/E, BKNG or VRTX?
- BKNG has the lower trailing P/E: BKNG trades at 19.29 and VRTX at 30.00. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BKNG or VRTX?
- Over the past five years, BKNG grew revenue faster — BKNG at a 31.52% CAGR versus VRTX at 13.57%.
- Does BKNG or VRTX pay a bigger dividend?
- BKNG pays a dividend (0.92% yield), while VRTX has no payments in the available dividend history.
- Is BKNG or VRTX more profitable?
- VRTX runs the higher net margin — BKNG at 25.53% versus VRTX at 34.89%.
- How have BKNG and VRTX total returns compared?
- Over the past 10 years, BKNG delivered 12.15% and VRTX delivered 18.72% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Booking P/E ratioVertex Pharmaceuticals P/E ratioBooking dividend yieldBooking ROEVertex Pharmaceuticals ROEBooking operating marginVertex Pharmaceuticals operating marginBooking revenue growthVertex Pharmaceuticals revenue growthBooking free cash flowVertex Pharmaceuticals free cash flow
Booking & Vertex Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 10, 2026.